Merck & Co., Inc. (NYSE:MRK) Shares Sold by Douglas Lane & Associates LLC


Share on StockTwits

Douglas Lane & Associates LLC cut its holdings in Merck & Co., Inc. (NYSE:MRK) by 0.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 463,535 shares of the company’s stock after selling 1,072 shares during the period. Douglas Lane & Associates LLC’s holdings in Merck & Co., Inc. were worth $37,917,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Massachusetts Financial Services Co. MA grew its stake in Merck & Co., Inc. by 2.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 24,053,883 shares of the company’s stock valued at $1,995,271,000 after purchasing an additional 538,791 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Merck & Co., Inc. by 16.7% during the third quarter. Nuveen Asset Management LLC now owns 20,139,807 shares of the company’s stock valued at $1,670,597,000 after purchasing an additional 2,882,982 shares during the last quarter. Morgan Stanley lifted its position in shares of Merck & Co., Inc. by 3.5% in the 3rd quarter. Morgan Stanley now owns 19,347,857 shares of the company’s stock worth $1,604,905,000 after buying an additional 653,675 shares during the last quarter. FMR LLC boosted its holdings in shares of Merck & Co., Inc. by 0.3% in the 2nd quarter. FMR LLC now owns 12,957,653 shares of the company’s stock valued at $1,002,015,000 after buying an additional 41,706 shares during the period. Finally, UBS Asset Management Americas Inc. grew its position in shares of Merck & Co., Inc. by 2.5% during the 3rd quarter. UBS Asset Management Americas Inc. now owns 12,491,648 shares of the company’s stock valued at $1,036,182,000 after buying an additional 308,003 shares during the last quarter. 66.43% of the stock is currently owned by institutional investors.

NYSE:MRK traded up $0.25 during trading hours on Thursday, hitting $82.59. 196,432 shares of the company’s stock traded hands, compared to its average volume of 10,221,937. Merck & Co., Inc. has a twelve month low of $65.25 and a twelve month high of $92.06. The firm has a market cap of $208.96 billion, a P/E ratio of 18.22, a P/E/G ratio of 1.96 and a beta of 0.43. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30. The stock’s fifty day moving average price is $81.41 and its two-hundred day moving average price is $81.11.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.44 by $0.30. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business had revenue of $12.55 billion during the quarter, compared to analyst estimates of $12.21 billion. During the same period last year, the company earned $1.51 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 1.2% compared to the same quarter last year. On average, equities research analysts predict that Merck & Co., Inc. will post 5.9 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th were issued a dividend of $0.65 per share. This represents a $2.60 dividend on an annualized basis and a yield of 3.15%. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.61. The ex-dividend date of this dividend was Monday, December 14th. Merck & Co., Inc.’s dividend payout ratio is 50.10%.

A number of equities analysts have commented on the company. Mizuho restated a “buy” rating and issued a $100.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, December 6th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, November 10th. JPMorgan Chase & Co. boosted their price target on shares of Merck & Co., Inc. from $98.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Truist assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, October 23rd. They set a “buy” rating and a $96.00 price target for the company. Finally, SVB Leerink lifted their price objective on shares of Merck & Co., Inc. from $100.00 to $103.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $95.36.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.

Featured Story: Return on Investment (ROI)

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.